The technology described is a sophisticated and high-throughput luciferase immunoprecipitation system (LIPS) assay designed to detect antibodies specific to Varicella-zoster virus (VZV) glycoprotein E (gE). By transfecting cells with VZV protein-Renilla luciferase fusion protein constructs and subsequently performing immunoprecipitations with protein A/G beads, this innovative assay enables the quantitative measurement of VZV gE antibody levels in blood serum samples. Notably, it demonstrates a sensitivity comparable to the established fluorescent antibody to membrane antigen test (FAMA), making it a promising tool for identifying anti-VZV antibodies in individuals who have received the VZV vaccine. However, potential patent challenges may arise due to similarities with assays used for related herpesviruses, and the market for this technology is relatively niche, primarily targeting populations at higher risk of VZV infection, such as pregnant women and healthcare workers.